Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection

[Business Wire] – Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for Sovaldi® 400 mg tablets, a once-daily oral nucleotide analogue polymerase inhibitor for the treatment of chronic . . . → Read More: Company Update – Gilead Sciences Inc. (NASDAQ:GILD) – European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection